Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril

What Was Tested

Researchers studied IGF-1 LR3 in this randomized controlled trial publication.

To determine whether the effect of angiotensin converting enzyme (ACE) inhibitors on left ventricular hypertrophy in patients with essential hypertension is related to ACE inhibitor effects on IGF-1 levels.

Who Took Part

The abstract describes 87 patients taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

The relationship between echocardiographically determined left ventricular hypertrophy and plasma IGF-1 levels was investigated in 87 patients with essential hypertension before and after 6 months of randomly allocated treatment with captopril (n = 30), lisinopril (n = 37) or quinapril (n = 20).

The control group consisted of 30 age- and sex-matched normotensive subjects without left ventricular hypertrophy.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.

A time span of 6 months appears in the methods.

What Was Measured

The subject headings attached to it are Angiotensin-Converting Enzyme Inhibitors, Captopril, Hypertension, Hypertrophy, Left Ventricular, Insulin-Like Growth Factor I, Isoquinolines and Lisinopril.

What This Means in Plain Language

The paper is a randomized study of IGF-1 LR3 in 87 patients over 6 months.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1994 (Journal of hypertension. Supplement : official journal of the International Society of Hypertension), a journal based in England.

More context: the IGF-1 LR3 compound page, all human trials.